
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
Keywords: EGFR; Erlotinib; EGFR-TKI; Gefitinib; KRAS; Non-small cell lung cancer;